Abeona Therapeutics, Common Stock
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public offering of 3,
Soleno Therapeutics Prices Public Offering Of 3 Mln Shares At $46/shr; Stock Down In After-hours
(RTTNews) - Soleno Therapeutics Inc. (SLNO) said that it has priced underwritten public offering of 3 million shares of its common stock at $46.00 per share. SLNO closed Thursday's regular trading at $49.23 up $1.69 or 3.55%. But in the after-hours trading the stock dropped $3.23 or 6.56%.
REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics ...
PWS is a rare genetic disorder that causes individuals to constantly eat because they don't feel full. It occurs in 1 in ...
Soleno Therapeutics, Inc.'s New Drug Application filing of DCCR for the treatment of patients with Prader-Willi Syndrome ...
C602 an open-label extension study enrolled participants who completed DESTINY PWS (C601), an international, multi-center, randomized, double-blind, placebo-controlled study of DCCR in 127 PWS ...
Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to indicate market sentiment and gauge the stock ...
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback